TScan Therapeutics, Inc.
TCRX
$1.60
-$0.12-6.98%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.82M | 9.36M | 12.20M | 14.81M | 21.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.82M | 9.36M | 12.20M | 14.81M | 21.05M |
| Cost of Revenue | 4.85M | 15.13M | 11.60M | 5.95M | 2.88M |
| Gross Profit | -2.03M | -5.76M | 596.00K | 8.86M | 18.17M |
| SG&A Expenses | 30.29M | 28.43M | 26.91M | 25.67M | 26.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 137.64M | 128.83M | 123.79M | 116.90M | 114.51M |
| Operating Income | -134.82M | -119.47M | -111.59M | -102.09M | -93.46M |
| Income Before Tax | -127.50M | -111.30M | -104.41M | -96.80M | -89.22M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -127.50 | -111.30 | -104.41 | -96.80 | -89.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -127.50M | -111.30M | -104.41M | -96.80M | -89.22M |
| EBIT | -134.82M | -119.47M | -111.59M | -102.09M | -93.46M |
| EBITDA | -130.71M | -114.79M | -106.66M | -96.97M | -88.10M |
| EPS Basic | -2.42 | -2.20 | -2.12 | -2.03 | -2.33 |
| Normalized Basic EPS | -1.50 | -1.37 | -1.32 | -1.27 | -1.46 |
| EPS Diluted | -2.42 | -2.20 | -2.12 | -2.03 | -2.33 |
| Normalized Diluted EPS | -1.50 | -1.37 | -1.32 | -1.27 | -1.46 |
| Average Basic Shares Outstanding | 210.78M | 202.02M | 196.49M | 190.77M | 167.09M |
| Average Diluted Shares Outstanding | 210.78M | 202.02M | 196.49M | 190.77M | 167.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |